|
1
|
Nickoloff BJ: The immunologic and genetic
basis of psoriasis. Arch Dermatol. 135:1104–1110. 2000.PubMed/NCBI
|
|
2
|
Sabat R, Philipp S, Höflich C, et al:
Immunopathogenesis of psoriasis. Exp Dermatol. 16:779–798. 2007.
View Article : Google Scholar
|
|
3
|
van Lingen RG, van de Kerkhof PC, de Jong
EM, et al: Reduced CD26 bright expression of peripheral blood CD8+
T-cell subsets in psoriatic patients. Exp Dermatol. 17:343–348.
2008.PubMed/NCBI
|
|
4
|
Berth-Jones J: The use of ciclosporin in
psoriasis. J Dermatolog Treat. 16:258–277. 2005. View Article : Google Scholar
|
|
5
|
Krueger JG, Wolfe JT, Nabeya RT, et al:
Successful ultraviolet B treatment of psoriasis is accompanied by a
reversal of keratinocyte pathology and by selective depletion of
intraepidermal T cells. J Exp Med. 182:2057–2068. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottlieb SL, Gilleaudeau P, Johnson R, et
al: Response of psoriasis to a lymphocyte-selective toxin
(DAB389IL-2) suggests a primary immune, but not keratinocyte,
pathogenic basis. Nat Med. 1:442–447. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abrams JR, Kelley SL, Hayes E, et al:
Blockade of T lymphocyte costimulation with cytotoxic T
lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses
the cellular pathology of psoriatic plaques, including the
activation of keratinocytes, dendritic cells, and endothelial
cells. J Exp Med. 192:681–694. 2000. View Article : Google Scholar
|
|
8
|
Gordon KB, Papp KA, Hamilton TK, et al:
Efalizumab for patients with moderate to severe plaque psoriasis: a
randomized controlled trial. JAMA. 290:3073–3080. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tomfohrde J, Silverman A, Barnes R, et al:
Gene for familial psoriasis susceptibility mapped to the distal end
of human chromosome 17q. Science. 264:1141–1145. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hüffmeier U, Steffens M, Burkhardt H, et
al: Evidence for susceptibility determinant(s) to psoriasis
vulgaris in or near PTPN22 in German patients. J Med Genet.
43:517–522. 2006.PubMed/NCBI
|
|
11
|
Bowcock AM: The genetics of psoriasis and
autoimmunity. Annu Rev Genomics Hum Genet. 6:93–122. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Galić Z, Kitchen SG, Subramanian A, et al:
Generation of T lineage cells from human embryonic stem cells in a
feeder free System. Stem Cells. 27:100–107. 2009.PubMed/NCBI
|
|
13
|
Kondo M, Weissman IL and Akashi K:
Identification of clonogenic common lymphoid progenitors in mouse
bone marrow. Cell. 91:661–672. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petrie HT and Zúñiga-Pflücker JC: Zoned
out: functional mapping of stromal signaling microenvironments in
the thymus. Annu Rev Immunol. 25:649–679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petrie HT: Cell migration and the control
of post-natal T-cell lymphopoiesis in the thymus. Nat Rev Immunol.
3:859–866. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang K, Li X, Yin G, et al: Functional
characterization of T cells differentiated in vitro from bone
marrow-derived CD34 cells of psoriatic patients with family
history. Exp Dermatol. 19:e128–e135. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang K, Zhang R, Li X, et al: The mRNA
expression and promoter methylation status of the p16 gene in
colony-forming cells with high proliferative potential in patients
with psoriasis. Clin Exp Dermatol. 32:702–708. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lacaud G, Gore L, Kennedy M, et al: Runx1
is essential for hematopoietic commitment at the hemangioblast
stage of development in vitro. Blood. 100:458–466. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Helms C, Cao L, Krueger JG, et al: A
putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is
associated with susceptibility to psoriasis. Nat Genet. 35:349–356.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanamori H, Tanaka M, Kawaguchi H, et al:
Resolution of psoriasis following allogeneic bone marrow
transplantation for chronic myelogenous leukemia: case report and
review of the literature. Am J Hematol. 71:41–44. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Woods AC and Mant MJ: Amelioration of
severe psoriasis with psoriatic arthritis for 20 years after
allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis.
65:6972006.PubMed/NCBI
|
|
22
|
Snowden JA and Heaton DC: Development of
psoriasis after syngeneic bone marrow transplant from psoriatic
donor: further evidence for adoptive autoimmunity. Br J Dermatol.
137:130–132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Byth KF, Conroy LA, Howlett S, et al:
CD45-null transgenic mice reveal a positive regulatory role for
CD45 in early thymocyte development, in the selection of
CD4+CD8+thymocytes, and B cell maturation. J Exp Med.
183:1707–1718. 1996.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)). Method. 25:402–408. 2001.
|
|
25
|
Ward V, Hennig BJ, Hirai K, et al:
Geographical distribution and disease associations of the CD45 exon
6 138G variant. Immunogenetics. 58:235–239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kishihara K, Penninger J, Wallace VA, et
al: Normal B lymphocyte development but impaired T cell maturation
in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell.
74:143–156. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hermiston ML, Xu Z and Weiss A: CD45: a
critical regulator of signaling thresholds in immune cells. Annu
Rev Immunol. 21:107–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pingel JT and Thomas ML: Evidence that the
leukocyte-common antigen is required for antigen-induced T
lymphocyte proliferation. Cell. 58:1055–1065. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weaver CT, Pingel JT, Nelson JO, et al:
CD8+ T-cell clones dificient in the expression of the CD45 protein
tyrosine phosphatase have impaired responses to T-cell receptor
stimuli. Mol Cell Biol. 11:4415–4422. 1991.
|
|
30
|
Koretzky GA, Kohmetscher MA, Kadleck T, et
al: Restoration of T cell receptor-mediated signal transduction by
transfection of CD45 cDNA into a CD45-deficient variant of the
Jurkat T cell line. J Immunol. 149:1138–1142. 1992.PubMed/NCBI
|
|
31
|
Montoya M, Dawes R, Reid D, Lee LN, Piercy
J, Borrow P, Tchilian EZ and Beverley PC: CD45 is required for type
I IFN production by dendritic cells. Eur J Immunol. 36:2150–2158.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen F, Xu XL, Graf LH, et al:
CD45-cross-linking stimulates IFN-gamma production in NK cells. J
Immunol. 154:644–652. 1995.PubMed/NCBI
|
|
33
|
Dawes R, Petrova S, Liu Z, et al:
Combinations of CD45 isoforms are crucial for immune function and
disease. J Immunol. 176:3417–3425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takahashi H, Tsuji H, Hashimoto Y,
Ishida-Yamamoto A and Iizuka H: Serum cytokines and growth factor
levels in Japanese patients with psoriasis. Clin Exp Dermatol.
35:645–649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Szegedi A, Aleksza M, Gonda A, et al:
Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFN-gamma
levels in psoriatic patients. Immunol Lett. 86:277–280. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Arican Ozer, Aral Murat, Sasmaz Sezai, et
al: Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17,
and IL-18 in patients with active psoriasis and correlation with
disease severity. Mediators Inflamm. 24:273–279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang K, Zhang R, Li X, et al: Promoter
methylation status of p15 and p21 genes in HPP-CFCs of bone marrow
of patients with psoriasis. Eur J Dermatol. 9:141–146.
2009.PubMed/NCBI
|
|
38
|
Yin G, Li J, Wan Y, et al: Abnormality of
RUNX1 signal transduction in psoriatic CD34+ bone marrow cells. Br
J Dermatol. 164:1043–1051. 2011.PubMed/NCBI
|
